


Data Sheet

Product Name:	ZM241385
Cat. No.:	CS-5528
CAS No.:	139180-30-6
Molecular Formula:	C ₁₆ H ₁₅ N ₇ O ₂
Molecular Weight:	337.34
Target:	Adenosine Receptor
Pathway:	GPCR/G Protein
Solubility:	DMSO : ≥ 30 mg/mL (88.93 mM)



BIOLOGICAL ACTIVITY:

ZM241385 is a potent, high affinity and selective adenosine **A_{2a} receptor (A_{2A}R)** antagonist with a K_i value of 1.4 nM^{[1][2][3]}. IC₅₀ & Target: K_i : 1.4 nM (A_{2A}R)^[2] **In Vitro**: ZM241385 (1 μM; 24 hours; PC12 cells) treatment reverses the phenomenon that A_{2A}R agonist CGS21680 significantly upregulates A_{2A}R mRNA levels^[1].

ZM241385 (1 μM; 48 hours; PC12 cells) treatment reverses the phenomenon that A_{2A}R agonist CGS21680 significantly increases A_{2A}R protein levels^[1]. **In Vivo**: ZM241385 (0.2 μg/mouse, 0.4 μg/mouse; intraperitoneal injection; every day; for 11 weeks; female C57BL/6 WT mice) treatment decreases tumor volume, activates CD8⁺ T cells and reduces the frequency of splenic MDSC^[4].

PROTOCOL (Extracted from published papers and Only for reference)

Enzyme assay [1] The activity of ZM 241385 was determined against a range of phosphodiesterase enzymes from rat hepatocytes and compared with the activity of theophylline. Isolated hepatocytes were prepared from fed male Sprague Dawley rats and incubated. Cells (3-5 mg dry weight/ml) were pre-incubated at 37°C for 20 min, with constant gassing (95% O₂/5% CO₂), before use. Cyclic AMP phosphodiesterase activity was measured by a modification of the two step procedure. All assays were performed at 30°C in the presence of cyclic AMP (1 μM). Animal administration [1] Dunkin Hartley guinea-pigs (male 250-400 g) were killed by cervical dislocation and their atria removed and immersed in Krebs solution. The atrial pairs were mounted in organ baths containing oxygenated Krebs solution (95% O₂/5% CO₂) at 37°C. The nucleoside transport inhibitor, dipyridamole (10 μM) was present in the Krebs solution since the agonist, 2-chloroadenosine (2-CADO) has been shown to be a substrate for the transporter. Adenosine deaminase (2 u/ml) was added to remove endogenous tissue adenosine. The spontaneously beating atria were placed under a resting tension of 1 g and allowed to equilibrate for 50 min with continuous overflow. 2-CADO (range 0.01 μM-10 μM) was administered to produce a slowing of atrial rate before and after incubation of test compound for 30 min (ZM 241385, 3 μM-30 μM). The affinity of ZM 241385 (10 μM) for atrial muscarinic receptors was determined using carbachol (0.01 μM-3 μM) concentration-response curves.

References:

[1]. Wang Z, et al. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PLoS One. 2010 Nov 8;5(11):e13883. doi: 10.1371/journal.pone.0013883.

[2]. Linden J, et al. Characterization of human A_{2B} adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.

[3]. Poucher SM, et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A_{2a} selective adenosine receptor antagonist. Br J Pharmacol. 1995 Jul;115(6):1096-102.

[4]. Ludwig S, et al. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. Cancer Immunol Immunother. 2019 Jul;68(7):1133-1141.

CAIndexNames:

Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-

SMILES:

OC1=CC=C(C(CNC2=NC3=NC(C4=CC=CO4)=NN3C(N)=N2)C=C1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA